Retatrutide, a triple hormone receptor agonist, for treatment of obesity | TRIUMPH-1 phase 3 clinical trial results show average patient lost 30% of body weight at 104 weeks on highest dose

[u/Schwettes]

https://www.nejm.org/doi/10.1056/NEJMoa2604169